Yesterday, Pacira Biosciences Inc (NASDAQ: PCRX) reversed some of the losses from the previous day to close the day with gains of 1.20%. This came after the company announced that, phase 4 for EXPAREL during C-Section operations had met its primary endpoints. It achieved this with a major reduction in the overall postsurgical opioid consumption, while at the same time retaining pain scores over 3 days.

The company further announced that, EXPAREL also met its secondary endpoints, and led to a decrease in the presence and intensity of itching in the first 3-days after surgery. The company also announced that, the whole study will be available for publishing in peer-reviewed medical journals in the course of the year.

The phase 4, randomized study was carried out at 18 clinical sites in the U.S.A. The study involved 169 patients that were going through elective C-section.  For the study, patients were selected in the ratio of 1:1:1 to either get 150mcg morphine spinal anesthesia, 50 mcg morphine spinal aesthesia plus EXPAREL or opioid-free anesthesia plus EXPAREL TAP block. On top of that, patients who received EXPAREL also got a postoperative pain management regime as defined by the protocol.  The regimen was made up of ketorolac, ibuprofen, and acetaminophen. The patients also had the freedom to get opioid pain medication if they requested it.

Commenting on the breakthrough, Pacira Biosciences CEO Dave Stack stated that, the provision of safe and operational non-opioid post-surgical pain management was essential to assisting new mothers to recover after a C-section. He added that, the results of the company’s study were supportive of the transformation of pain management for new mothers who have undergone a C-section.

Going by its price action, PCRX did not record much movement after the announcement. It gained marginally by 1.20% to close the day at $43.10. Volumes in the day were 497.99k.

About Pacira Biosciences Inc

Pacira BioSciences Inc is a biopharma company that offers non-opioid pain management solutions. It is based in Parsippany, New Jersey.